Commentary: T Cells Regulate Lung Transplant Rejection in Mice and Men

Jason M. Gauthier,Wenjun Li,Daniel Kreisel

DOI: https://doi.org/10.1016/j.jtcvs.2019.01.101

2019-01-01

Abstract:Central MessageLung transplant acceptance appears to be facilitated by regulatory T cells in both humans and mice, suggesting a novel means of preventing chronic rejection.See Article page 2528. Lung transplant acceptance appears to be facilitated by regulatory T cells in both humans and mice, suggesting a novel means of preventing chronic rejection. See Article page 2528. Since the advent of lung transplantation, chronic lung allograft dysfunction (CLAD) has been the number one cause of long-term mortality.1Christie J.D. Edwards L.B. Kucheryavaya A.Y. Aurora P. Dobbels F. Kirk R. et al.The registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report—2010.J Heart Lung Transplant. 2010; 29: 1104-1118Abstract Full Text Full Text PDF PubMed Scopus (402) Google Scholar A subset of T cells, known as regulatory T cells (Tregs), have been shown to suppress inflammatory responses after organ transplantation. Much of what is known about the role of Tregs in suppressing alloimmune responses has come from experimental studies of kidney, heart, pancreatic islet, liver, and bone marrow transplantation. On the basis of these findings, 2 phase I clinical trials in which adoptively transferred Tregs were administered after kidney transplantation have been completed.2Chandran S. Tang Q. Sarwal M. Laszik Z.G. Putnam A.L. Lee K. et al.Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants.Am J Transplant. 2017; 17: 2945-2954Crossref PubMed Scopus (128) Google Scholar, 3Mathew J.M. H-Voss J. LeFever A. Konieczna I. Stratton C. He J. et al.A phase I clinical trial with ex vivo expanded recipient regulatory t cells in living donor kidney transplants.Sci Rep. 2018; 8: 7428Crossref PubMed Scopus (135) Google Scholar Such clinical progress has yet to be made for lung transplantation, however, because the role of Tregs in this setting is just beginning to emerge. In 2017, Abrams and colleagues4Abrams K.V. Hwang B. Nash R.A. Georges G.E. Lamm W. Storer B. et al.The use of ex vivo generated regulatory T-cell preparations in a canine lung allograft model.Transplantation. 2017; 101: e326-e327Google Scholar performed a series of canine lung transplants mismatched for minor histocompatibility antigens without immunosuppression and infused recipient-derived, in vitro major histocompatibility antigen–primed Tregs cells that were selected on the basis of their expression of CD25, a putative surface marker of Tregs, shortly after graft reperfusion. They found that allograft survival correlated with the in vitro suppressive capacity of the infused Tregs. Shortly thereafter, Warnecke's group at Hannover Medical School,5Salman J. Ius F. Knoefel A.K. Sommer W. Siemeni T. Kuehn C. et al.Association of higher CD4+ CD25high CD127low, FoxP3+, and IL-2+ T cell frequencies early after lung transplantation with less chronic lung allograft dysfunction at two years.Am J Transplant. 2017; 17: 1637-1648Crossref PubMed Scopus (30) Google Scholar one of the most distinguished lung transplant centers in the world, reported that an increased frequency of peripheral Tregs shortly after lung transplantation in human patients is associated with protection from CLAD. To study these findings, this group recently established an elegant model of transplant atherosclerosis in humanized mice, whereby peripheral leukocytes from a human lung recipient are transferred into an immunodeficient mouse that receives a segment of a pericardiophrenic artery from the human lung donor. With this model, the Hannover researchers have shown that transfer of recipient-derived leukocyte preparations rich in Tregs abrogates atherosclerosis of the human donor arterial segments.6Siemeni T. Knöfel A.K. Madrahimov N. Sommer W. Avsar M. Salman J. et al.In vivo development of transplant arteriosclerosis in humanized mice reflects alloantigen recognition and peripheral Treg phenotype of lung transplant recipients.Am J Transplant. 2016; 16: 3150-3162Scopus (13) Google Scholar In this issue of the Journal, Siemeni and colleagues7Siemeni T. Knöfel A.K. Ius F. Sommer W. Salman J. Böthig D. et al.Transplant arteriosclerosis in humanized mice reflects chronic lung allograft dysfunction and is controlled by regulatory T cells.J Thorac Cardiovasc Surg. 2019; 157: 2528-2537Abstract Full Text Full Text PDF Scopus (8) Google Scholar from the Hannover lung transplant group extend these findings to show that leukocyte preparations taken from patients who ultimately develop CLAD results in more severe atherosclerosis of the transplanted arterial segment in the humanized mice. Perhaps more importantly, they have found that adoptive transfer of Treg-enriched leukocyte preparations is able to abrogate this process. In our own laboratory, we have observed that lymphoid follicles rich in Tregs are abundant in both human and mouse lung transplant grafts that are accepted long term.8Li W. Bribriesco A.C. Nava R.G. Brescia A.A. Ibricevic A. Spahn J.H. et al.Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis.Mucosal Immunol. 2012; 5: 544-554Crossref PubMed Scopus (57) Google Scholar When we selectively deplete lung-resident Tregs from tolerant murine pulmonary allografts, they develop antibody-mediated rejection, associated with small airway destruction reminiscent of CLAD in human recipients.9Li W. Gauthier J.M. Higashikubo R. Hsiao H.M. Tanaka S. Vuong L. et al.Bronchus-associated lymphoid tissue-resident Foxp3+ T lymphocytes prevent antibody-mediated lung rejection.J Clin Invest. 2019; 129: 556-568Crossref PubMed Scopus (35) Google Scholar These observations have suggested that the immune tolerance conveyed by Tregs occurs locally within allografts, which is distinctly different from other solid-organ transplants, in which immune regulation occurs in peripheral lymphoid tissues. Our findings reinforce those of Siemeni and colleagues7Siemeni T. Knöfel A.K. Ius F. Sommer W. Salman J. Böthig D. et al.Transplant arteriosclerosis in humanized mice reflects chronic lung allograft dysfunction and is controlled by regulatory T cells.J Thorac Cardiovasc Surg. 2019; 157: 2528-2537Abstract Full Text Full Text PDF Scopus (8) Google Scholar to suggest that deleterious alloimmune responses after lung transplantation are suppressed by Tregs and set the stage for tolerance. Novel strategies that enrich Tregs after human lung transplantation are called for, and we hope these recent findings will lead to clinical trials in the near future. Transplant arteriosclerosis in humanized mice reflects chronic lung allograft dysfunction and is controlled by regulatory T cellsThe Journal of Thoracic and Cardiovascular SurgeryVol. 157Issue 6PreviewChronic lung allograft dysfunction (CLAD) is a severe complication of lung transplantation limiting long-term survival. We studied correlations between CLAD after clinical lung transplantation and leukocyte-mediated development of transplant arteriosclerosis (TA) in a humanized mouse model. The pericardiophrenic artery was procured from surplus tissue of donor lungs (n = 22) transplanted in our clinical program and was implanted into the abdominal aorta of immune-deficient mice. Full-Text PDF Open Archive